| Bioactivity | JB300 is a highly selective Aurora A degrader based on PROTAC technology (DC50=30 nM). JB300 can be used for tumor research. JB300 consists of PROTAC target protein ligand MK-5108 (HY-13252) (pink part), E3 ligase ligand Thalidomide-O-COOH (HY-103597) (blue part) and PROTAC Linker Boc-NH-PEG2-C2-NH2 (HY-W008474) (black part), of which the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-O-COOH-NH2-C2-PEG2-NH-Boc (HY-172145)[1]. |
| CAS | 3038446-90-8 |
| Formula | C43H45ClFN7O10S |
| Molar Mass | 906.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bozilovic, et al. "Novel, highly potent PROTACs targeting AURORA-A kinase." Current Research in Chemical Biology 2 (2022): 100032. |
JB300
CAS: 3038446-90-8 F: C43H45ClFN7O10S W: 906.37
JB300 is a highly selective Aurora A degrader based on PROTAC technology (DC50=30 nM). JB300 can be used for tumor resea
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.